LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$15.70 USD
-0.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LENZ 15.70 -0.02(-0.13%)
Will LENZ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LENZ
Lenz Therapeutics management to meet with Piper Sandler
LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for LENZ Therapeutics Amidst Strong Clinical Progress and Market Potential
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)